IL33, identified as a key prognostic marker, suppresses tumor growth and enhances immune-mediated tumor destruction, underscoring the dual role of efferocytosis in both promoting immunosuppression and revealing therapeutic vulnerabilities [5]. This evidence concerns the gene IL33 and neoplasm.